AU2020263869A1 - Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases - Google Patents
Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases Download PDFInfo
- Publication number
- AU2020263869A1 AU2020263869A1 AU2020263869A AU2020263869A AU2020263869A1 AU 2020263869 A1 AU2020263869 A1 AU 2020263869A1 AU 2020263869 A AU2020263869 A AU 2020263869A AU 2020263869 A AU2020263869 A AU 2020263869A AU 2020263869 A1 AU2020263869 A1 AU 2020263869A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- acid
- treatment
- compounds
- cpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| GB1905711.6 | 2019-04-24 | ||
| PCT/EP2020/061083 WO2020216740A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020263869A1 true AU2020263869A1 (en) | 2021-12-23 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020263869A Abandoned AU2020263869A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12383544B2 (https=) |
| EP (1) | EP3958863B1 (https=) |
| JP (1) | JP7543304B2 (https=) |
| KR (1) | KR20220004111A (https=) |
| CN (1) | CN113727711A (https=) |
| AU (1) | AU2020263869A1 (https=) |
| BR (1) | BR112021021117A2 (https=) |
| CA (1) | CA3137445A1 (https=) |
| ES (1) | ES2982398T3 (https=) |
| GB (1) | GB201905711D0 (https=) |
| IL (1) | IL287392A (https=) |
| MA (1) | MA55752A (https=) |
| MX (1) | MX2021012544A (https=) |
| PH (1) | PH12021552680A1 (https=) |
| SG (1) | SG11202111739VA (https=) |
| WO (1) | WO2020216740A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096453A1 (en) * | 2023-10-30 | 2025-05-08 | Vertex Pharmaceuticals Incorporated | Compounds for the treatment of kidney disease |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥（香港）有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| EP2464354B1 (en) * | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| TWI704919B (zh) * | 2012-05-31 | 2020-09-21 | 日商大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
| US10174012B2 (en) * | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| US10130622B2 (en) * | 2015-10-09 | 2018-11-20 | Abbvie S.Á.R.L. | Compounds for treatment of cystic fibrosis |
| AU2016333855A1 (en) | 2015-10-09 | 2018-04-26 | AbbVie S.à.r.l. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| WO2018237174A2 (en) * | 2017-06-21 | 2018-12-27 | The Johns Hopkins University | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 PH PH1/2021/552680A patent/PH12021552680A1/en unknown
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
- 2020-04-21 US US17/605,623 patent/US12383544B2/en active Active
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/en active Active
- 2020-04-21 ES ES20721493T patent/ES2982398T3/es active Active
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko not_active Withdrawn
- 2020-04-21 CA CA3137445A patent/CA3137445A1/en active Pending
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 JP JP2021562854A patent/JP7543304B2/ja active Active
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/en not_active Ceased
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL287392A (en) | 2021-12-01 |
| SG11202111739VA (en) | 2021-11-29 |
| MX2021012544A (es) | 2021-11-12 |
| MA55752A (fr) | 2022-03-02 |
| KR20220004111A (ko) | 2022-01-11 |
| GB201905711D0 (en) | 2019-06-05 |
| EP3958863B1 (en) | 2024-07-03 |
| CA3137445A1 (en) | 2020-10-29 |
| WO2020216740A1 (en) | 2020-10-29 |
| CN113727711A (zh) | 2021-11-30 |
| US20220202802A1 (en) | 2022-06-30 |
| EP3958863C0 (en) | 2024-07-03 |
| PH12021552680A1 (en) | 2022-07-04 |
| JP7543304B2 (ja) | 2024-09-02 |
| BR112021021117A2 (pt) | 2021-12-14 |
| US12383544B2 (en) | 2025-08-12 |
| EP3958863A1 (en) | 2022-03-02 |
| ES2982398T3 (es) | 2024-10-16 |
| JP2022529814A (ja) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11407782B2 (en) | Oxysterols and methods of use thereof | |
| AU2020378407B2 (en) | Heterocyclic RIP1 inhibitory compounds | |
| CA2974853C (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| UA128751C2 (uk) | Інгібітори rip1k | |
| EP2982675B1 (en) | Salt of pyrazoloquinoline derivative, and crystal thereof | |
| ES2798424T3 (es) | Compuestos de triazolopiridina y usos de estos | |
| EA017805B1 (ru) | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| EP3027614A1 (de) | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen | |
| JPWO2007102531A1 (ja) | 併用薬 | |
| EA017818B1 (ru) | ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| US12383544B2 (en) | Methods for the treatment of polycystic kidney disease | |
| AU2013296627A1 (en) | Deuterated ibrutinib | |
| WO2021060453A1 (ja) | 架橋型光学活性２級アミン誘導体 | |
| CA2950724A1 (en) | Naphthyridinedione derivatives | |
| EA017117B1 (ru) | 2-АМИНО-3-СУЛЬФОНИЛТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИДОПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT-РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| EA017968B1 (ru) | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| KR20230067637A (ko) | 근이영양증을 치료하기 위한 조성물 및 방법 | |
| RU2369600C1 (ru) | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| WO2015193228A1 (de) | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe | |
| EP3700890A1 (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| DE102017005089A1 (de) | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one | |
| EA017630B1 (ru) | ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT-РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| EA018944B1 (ru) | Замещенные 8-сульфонил-2,3,4,5-тетрагидро-1н-гамма-карболины, лиганды, фармацевтическая композиция, способ их получения и применения | |
| CA3038657C (en) | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors | |
| WO2025151602A1 (en) | Heteroaryl compounds as ligand directed degraders of irak4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |